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Abstract
A group of styrylquinolines were synthesized and tested for their anti-proliferative activity.
Anti-proliferative activity was evaluated against the human colon carcinoma cell lines that
had a normal expression of the p53 protein (HCT116 p53+/+) and mutants with a disabled
TP53 gene (HCT116 p53-/-) and against the GM 07492 normal human fibroblast cell line. A
SAR study revealed the importance of Cl and OH as substituents in the styryl moiety. Sev-
eral of the compounds that were tested were found to have a marked anti-proliferative activ-
ity that was similar to or better than doxorubicin and were more active against the p53 null
than the wild type cells. The cellular localization tests and caspase activity assays suggest
a mechanism of action through the mitochondrial pathway of apoptosis in a p53-indepen-
dent manner. The activity of the styrylquinoline compounds may be associated with their
DNA intercalating ability.
Introduction
Styrylquinolines are interesting quinoline-related compounds that have a broad spectrum of
biological activity [1–7]. The anti-proliferative effect of quinoline-5,8-diones and styrylquino-
line-carboxylic acids on tumor cell lines have been observed [8,9]. In this respect, compound I
(Fig 1) demonstrated a marked anti-proliferative effect with IC50 = 0.77 μM (SK-N-MC cell
line) [7]. More recently, we presented a similar series of compounds that also appeared to be
active. Among them the analog of II (R = H, R1 = OH) shown activity at micromolar level IC50
= 1.5 μM (HCT116 p53+/+ cell line) [9]. Another very important group to be mentioned here
are quinolinediones. This moiety is the main fragment of lavendamycin and related com-
pounds, which are known for their broad spectrum of activity and a series of 7-amino-quinal-
dine-5,8-diones whose anti-proliferative activity has been reported [8,10–13]. Among these,
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compound IV appeared to be active (IC50 = 1.44 μM; P388 cell line) [8]. Jiang et al. synthesized
a large series of quinazolines (II) in a search for new tubulin polymerization inhibitors [14]
and some were found to be highly active against L1210 leukemia cells. 6-methoxyderivative (II,
R = OMe, R1 = H) showed activity at micromolar concentrations (IC50 = 3.59 μM).
The styrylquinazoline CP-31398 is a small molecule with a unique ability to stabilize and
activate the p53 protein even in some cell lines with mutant p53. The p53 is a tumor suppressor
protein that is responsible for initiating growth arrest, DNA repair or apoptosis. It is induced
by various endo- and exogenous factors such as DNA damage, radicals, radiation and thermal
or chemical stress. Roughly 50% of all cancers have mutated the TP53 gene, which has been
connected with drug resistance and a poor prognosis [15]. Structurally diverse agents from
small organic molecules to oligopeptides that can reactivate the altered protein in TP53
mutated cells [16–18] are well known. Their activity opens fascinating new possibilities in anti-
cancer treatment. The compound CP-31398 has been broadly studied for its potency in restor-
ing the mutant p53 functions, e.g., its sequence-specific binding ability to DNA [19–23].
However, it has also been reported that TP53 may be upregulated in response to CP-31398
treatment [24]. Concluding, styrylquinazoline CP-31398 is cytotoxic against wild-type or
mutant cells but not in cells where TP53 is deleted (p53-null or p53-/-) due to its specific mech-
anism of action [24,25]. As was shown by Luu and coworkers, this compound is several times
less active against HCT116 p53-/- cells than against their wild-type (p53+/+) counterparts [26].
A minute activity in null cells has been suggested to rely on the formation of ROS or activation
of another proteins as p63 or p73 [24,27]. The last suggestion should, however, be rejected after
the verifying report of Demma et al [22].
Materials and Methods
All of the reagents were purchased from Sigma Aldrich. A Kieselgel 60, 0.040–0.063 mm
(Merck, Darmstadt, Germany) was used for the column chromatography. TLC experiments
were performed on alumina-backed silica gel 40 F254 plates (Merck, Darmstadt, Germany).
The plates were illuminated under UV (254 nm) and evaluated in iodine vapor. The melting
points were determined on an Optimelt MPA-100 apparatus (SRS, Stanford CA). The purity of
the final compounds was determined using HPLC. Detection wavelengths of 210 and 250 nm
were chosen for detection. The purity of individual compounds was determined from the area
peaks in the chromatogram of the sample solution in order to ensure>95% purity. UV spectra
(λ, nm) were determined on aWaters Photodiode Array Detector 2996 (Waters Corp., Milford,
MA, U.S.A.) in a methanolic solution (ca. 6×10-4mol) and log ε (the logarithm of molar
absorption coefficient, ε) was calculated for the absolute maximum λmax of the individual
Fig 1. Quinolines and analogs with a marked anticancer activity.
doi:10.1371/journal.pone.0142678.g001
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target compounds. All NMR spectra were recorded on a Bruker AM-400 (399.95 MHz for 1H
and 100 MHz for 13C), BrukerBioSpin Corp., Germany. Chemical shifts are reported in ppm
(δ) against the internal standard, Si(CH3)4. Easily exchangeable signals were omitted when
they were diffuse. Signals are designated as follows: s, singlet; d, doublet; dd, doublet of dou-
blets; t, triplet; m, multiplet; bs, broad singlet. The detailed information on all compounds are
presented in S1 File.
Synthesis
The designed styrylquinolines were prepared from quinaldines in acetic anhydride according
to a general procedure.
General method A. The appropriate quinoline derivative (2.5 mmol) in acetic anhydride
was thoroughly mixed with two equiv aldehyde and heated in an inert gas atmosphere (N2) for
16 h at 130°C. Then, the mixture was evaporated to dryness and a solid was crystallized from
EtOH.
Hydrolysis of acetoxy groups.
General method B. The crude product from step A was transferred to a mixture of pyri-
dine and water at a ratio of 3:1 and further heated for 3 h at 100°C. Then, the mixture was evap-
orated to dryness and a solid was crystallized or chromatographed.
General method C. The appropriate styrylquinoline derivative (2.5 mmol) in methanol
was thoroughly mixed with 2.5 equiv K2CO3 for 2 h at room temperature. Then, concentrated
HCl was added and the resulting precipitate was filtered and washed with H2O. The crude
product was crystallized from EtOH.
UV-VIS spectroscopy
The absorption and fluorescence spectra were determined using U-2900 and F-7000 spec-
trometers (Hitachi), respectively. Measurements were performed at room temperature in a
10-mm quartz cell with spectroscopic grade dimethyl sulfoxide (DMSO) applied as a solvent.
The most important parameters that were established from registered spectra are summarized
in S1 Table.
Cell lines
The human colon adenocarcinoma cell line HCT116 along with wild type p53 (p53+/+) were
obtained from the ATCC. The normal human fibroblast cell line GM 07492 and HCT116 with
a p53 deletion (p53-/-) were kindly provided by prof. M. Rusin fromMaria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology in Gliwice, Poland. Cells were grown as
monolayer cultures in 75 cm2 flasks (Nunc) in Dulbecco’s modified Eagle’s medium with an
antibiotic gentamicin (200 μL/100 mL medium). DMEM for HCT116 were supplemented with
12% heat-inactivated fetal bovine serum (Gibco) and for GM 07492 with 15% fetal bovine
serum (Gibco). Cells were cultured under standard conditions at 37°C in a humidified atmo-
sphere at 5% CO2.
Biological activity measurements
MTS assay. The cells were seeded in 96-well plates 24 h before the addition of the com-
pounds that were tested. The assay was performed following a 72 h incubation with varying
concentrations of the agents that were tested. The results were calculated as IC50 values (using
GraphPad Prism 5). Each individual compound was tested in triplicate in a single experiment
with each experiment being repeated three times. After a 72 h incubation with the compounds
Styrylquinolines as Anticancer Agents
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that were tested, 20 μL of The CellTiter 961AQueous One Solution—MTS (Promega) solution
was added to each well (with 100 μL DMEM without phenol red) and incubated for 1 h at
37°C. The optical densities of the samples were analyzed at 490 nm. Results were expressed as a
percentage of the control. The inhibitory concentration (IC50) was defined as the compound
concentration that was necessary to reduce the proliferation of cells to 50% of the untreated
control. The results are summarized in Table 1.
Subcellular localization. Compound localization in living cell cultures was studied using
fluorescence microscopy. Cells were seeded at a density of 20,000 cells/well on 8-well Lab-Tek
chambered coverglasses (Nunc). After 18 h, a medium containing the compounds at a concen-
tration that inhibits 50% viability of cells was added for an additional 2 h (standard conditions).
Then the cells were rinsed with PBS (pH 7.2) and a serum-free medium that contained Mito-
Tracker1Orange CMTMRos dye (100 nM, 30-min incubation, Molecular Probes) was added.
After incubation, the cells were washed twice with PBS and maintained in a phenol-free
medium. Image observation was carried out immediately after staining using a confocal
Table 1. Anti-cancer activity of the studied compounds (ND—not determined).
Compounds Activity IC50 [μM]
No R1/R2 HCT116 (p53
+/+) HCT116 (p53-/-) GM 07492
1a -/2-OH 17.45±2.20 14.05±2.24 >25
2a -/4-OEt >25 >25 ND
3a -/4-OBu >25 >25 ND
1b H/3,5-OMe >25 >25 ND
2b Ac/2-OAc 8.08±0.56 14.71±1.74 6.92±1.72
3b H/2-OAc 7.32±1.01 13.53±0.81 >25
4b H/3-OAc 7.88±1.98 10.73±3.76 >25
5b H/2,3-Cl 5.13±1.41 2.99±0.61 >25
6b H/3,4-Cl 9.41±2.17 3.34±0.58 >25
7b H/3,4-OAc,5-OMe >25 >25 ND
8b Ac/2,4-OAc >25 >25 ND
9b H/2,4,6-OH >25 >25 ND
10b Ac/2,4,6-OAc >25 >25 ND
11b H/2-F 15.43±2.46 8.38±1.12 >25
12b Ac/2-F 12.07±3.02 5.78±0.78 >25
13b H/3-OMe 24.60±4.36 18.42±1.36 >25
14b Ac/2,3,4-OAc 17.88±1.67 11.36±1.02 ND
15b H/2-OEt 15.81±3.32 12.80±3.53 ND
16b H/4-OEt >25 16.11±4.84 ND
17b H/2-Cl 9.84±1.79 7.97±3.24 20.17±6.52
18b H/2-OH 16.07±0.88 15.25±1.31 ND
19b H/3-OH 16,31±0,76 10.62±1.23 ND
20b H/2,4-OH >25 >25 ND
1c -/2-OEt 5.93±0.97 3.25±1.81 >25
2c -/2-Cl 1.88±0.85 2.86±1.00 12.57±2.88
3c -/4-OEt 2,23±0.81 3.53±0.83 >25
Doxorubicin 5.95±0.5 1.65±0.21 3.38±1.29
CP-31398 18.63±0.92 26.28±1.41 12.26±0.54
Results are expressed as mean ± SD of at least three independent experiments. IC50 values below 10 μM are bolded.
doi:10.1371/journal.pone.0142678.t001
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LSM700 system (Carl Zeiss). Additionally, an inverted fluorescence microscope (IX81, Olym-
pus) equipped with a CO2 incubator (temperature, humidity and gas flow under control) was
used to confirm the mitochondrial localization of compounds that was tested. In addition to
the MitoTracker1Orange CMTMRos dye, LysoTracker1Yellow-HCK-123 dye (5 μM, 1 h
incubation, Molecular Probes) was applied.
Caspase activity assay. To measure caspase-3 and -7 activities, a luminescent Caspase-Glo
3/7 assay was performed. HCT116 (p53+/+) and (p53-/-) cells were seeded onto black 96-well
plates at a density of 3,500 cells/well. After 24 h the compounds that were tested (2c, 3c, 3b, 4b,
5b, 6b, 13b, CP-31398) and a reference (doxorubicin) at IC50 concentration were added. After
48 h a Caspase-Glo 3/7 Assay (Promega) was performed according to the manufacturer’s
instructions. After adding 100 μL of Caspase3/7 GloReagent, cells were incubated for 2.5 h at
room temperature. The luminescence was measured using a multi-plate reader (Synergy 4, Bio
Tek) with an integration time of 1 second per well. The experiments were performed in
duplicate.
Immunoblotting. Specific antibodies were purchased from Sigma-Aldrich (anti-PARP,
anti-tubulin and peroxidase-labeled secondary antibodies). Briefly, cellular lysates were pre-
pared by harvesting cells in a Laemmli sample buffer. Proteins were separated on SDS-poly-
acrylamide gels and electroblotted onto nitrocellulose membranes. After blocking, the
membranes were incubated with specific primary antibodies overnight, washed and then incu-
bated with peroxidase-conjugated secondary antibodies. Finally, peroxidase activity was
detected with ECL+ reagents (AP Biotech) using a CCD camera LAS-4000 (Fujifilm).
Intercalation. For the DNA binding studies, Calf-thymus DNA (CT-DNA) was purchased
from Sigma Aldrich. The lyophilized CT-DNA was dissolved in 10 mM Tris-HCl, pH 7.9,
mixed gently and left overnight at 4°C. Then, the concentration of CT-DNA was determined
from the absorbance at 260 nm using an extinction coefficient of 6600 M-1cm-1. Compounds
2c, 3c, 5b, 6b, CP-31398 and doxorubicin were dissolved in DMSO to a concentration of 8.35
mM, which were then used as the stock solution for the preparation of the various concentra-
tions (25 μM; 12,5 μM; 6 μM) in 1 mL in 10 mM Tris-HCl (pH 7.9). Afterwards, 18 μM
CT-DNA was added to the prepared solutions and were incubated for 1.5 h at 37°C with occa-
sional vortexing. Absorption spectra were measured using a Hitachi U-2900 spectrophotome-
ter in range of 200–600 nm. All absorption spectra were imported and compared in OriginPro
8.0. Results are shown in S3 Table.
Statistical analysis. The analysis of cell viability was performed using GraphPad Prism
v.5.0 software (GraphPad Software, USA). The normality of variable distribution was assessed
using the Shapiro-Wilk test. The non-parametric Mann-Whitney test was applied to detect sig-
nificant differences between mean values.
Results and Discussion
Design and synthesis
Based on our experience in the design and synthesis of biologically active stryrylquinolines and
their structural similarity to CP-31398, we decided to screen the series of compounds on
human colon cancer lines, wild-type and p53 negative. The results were, however, unexpected
and lead to some interesting remarks. The compounds that were used in this study were
obtained during our search for active styrylquinolines as published recently [2,7,28–33]. As
this experiment was concentrated on the styryl part of the molecule, we modified it according
to the idea that is depicted in Fig 2. Series of nine new compounds were obtained to fill the gap
in the library of structures. Furthermore, we decided to evaluate dihalogenated compounds
based on the 5,7-dichloroquinoline scaffold. The rationale for this was our recent findings on
Styrylquinolines as Anticancer Agents
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their potency [2]. Such a scaffold was also reported in the work of Arafa et al. in which struc-
ture III with IC50 = 4.7 μMwas found to be promising against colon cancer cells. The impor-
tance of C-8 OH substitution was also studied here on the basis of the recent report of Chan
et al. [34].
The designed compounds were synthesized from the commercially available quinaldines: A,
B and C. The first step of this synthesis consisted of condensation with the appropriate alde-
hyde in acetic anhydride in reflux conditions. In this solvent, all of the hydroxyl groups that
were present in the substrates were acetylated. These groups were selectively removed with pyr-
idine/water or K2CO3/methanol mixtures (Fig 3).
Biological studies
The anti-proliferative activity of the synthesized compounds was tested with the MTS assay
against the human colon carcinoma (HCT116) cell lines, wild-type and p53 negative. Addition-
ally, the compounds were also tested for their cytotoxicity against normal cells—human fibro-
blasts (GM 07492). The results from the anti-proliferative activity assays are shown in Table 1
and S2 Table. All of the compounds could be divided into three groups (A, B, C) according to
their structural scaffolds (Fig 2). The biological activity results are in agreement with this distri-
bution. In general, compounds from group A can be regarded as inactive, while those from
group C are the most active. Group B is more extensive because of its substituents and the
activity spectrum. C-8 unsubstituted quinoline does not induce activity. 8-hydroxyquinoline or
its dichloro-analog is a good scaffold for active structures. The acetylation of 8-OH apparently
has no effect on activity at least within group B (compare 2b-3b or 11b-12b). The styryl part of
Fig 2. Synthesis of the compounds that were studied.
doi:10.1371/journal.pone.0142678.g002
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the molecule should be substituted with halogen. Interestingly, an additional chlorine atom
enhanced the activity (5b vs 17b). The acetoxy group in the phenyl ring also had a positive
effect on activity; however, a C-4 (15b vs 16b) substitution as well as multisubstituted patterns
(3b-5b vs 8b, 10b) decreased activity. The majority of the compounds that were tested were
non-toxic to nonmalignant cells within the concentrations that were tested.
Some relationships with their lipophilicity could be drawn for the active compounds. In Fig
4, we present the active compounds (logIC50) plotted against their lipophilicity. All of the com-
pounds with a similar potency to standard doxorubicin have LogP above 4.5. The more lipo-
philic the compounds were, the higher their antiproliferative activity. However, the shape of
dependence may be astonishing. In general, according to the literature, a plateau should be
observed at higher LogP values or even a decrease in the activity in the Gaussian shape function
[35,36]. This, however, can be explained. First of all, in Fig 4, we plotted only the active
Fig 3. Selective hydrolysis of styrylquinolines. For example, compare 2b, 3b and 18b.
doi:10.1371/journal.pone.0142678.g003
Fig 4. Activity (as—logIC50) vs logP of the compounds that were tested.
doi:10.1371/journal.pone.0142678.g004
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compounds and therefore the range of lipophilicity is relatively narrow. However, the action of
these compounds may be revealing in membranes or other more lipophilic structures and thus
favor more lipophilic agents.
The effect of the TP53 status on a cells’ susceptibility to styrylquinolines seems to be espe-
cially interesting. Those that were halogenated in the phenyl ring (5b, 6b, 11b and 12b) were
roughly 2–3 times more effective against HCT116 (p53-/-) than against the wild type cells. On
the other hand, the acetoxy group in the phenyl ring decreased the activity against the mutants
(2b-4b). Compounds from group C had approximately the same level of activity regardless of
the p53 status. Only the 2-ethoxy derivative (1c) was more active against the p53 null cells in
this group, but the differences were too small to draw more serious remarks. On the other
hand, the p53 reactivator CP-31398 appeared to be significantly less active against the mutant
cells which is in agreement with previous results [24,26].
A possible explanation is that styrylquinolines can activate a downstream signal cascade in a
p53-independent manner. This hypothesis is somewhat supported by lipophilicity—an activity
relationship that prefers the more lipophilic compounds (see Fig 4). Slightly more lipophilic
and basic compounds may easily penetrate and disorganize the mitochondrial membrane [37]
thus affecting the release of the signal transducers that are involved in the intrinsic apoptosis
pathway [38]. Fortunately, several of the compounds that were tested showed good fluores-
cence in the violet-blue wavelengths (see S1 Table). This prompted us to perform cellular local-
ization experiments (Fig 5 and S1 Fig).
The micrographs that are presented show the subcellular localization of the 6b compound
following staining with fluorescent organelle-specific dyes that accumulated selectively in mito-
chondria. After a two-hour incubation, the compound penetrated into the cell interior effi-
ciently and an intense blue fluorescence that originated from the internalized compound was
observed. This is the way that the MitoTracker Orange CMTMRos dye and styrylquinoline
accumulates in the mitochondria of healthy cells. Observation of the combined channels con-
firmed the mitochondrial localization of the studied compounds. If this hypothesis is correct,
the post-mitochondrial pathway of apoptosis should be activated.
The release of cytochrome c from mitochondria leads to the activation of caspase 9, and
subsequently caspases 3 and 7. On the other hand, caspase 9 may be activated by caspase 3
later in an autostimulant feedback [39]. Caspase 3 is responsible for the amplification of the
whole cascade, thus its activation is called the “point of no return” [40]. Alternatively, other
factors may be released from the mitochondria membrane, e.g., the apoptosis-inducing factor
AIF or endonuclease G, which are effectors of a caspase-independent apoptosis that is driven
by DNA fragmentation without the activation of the caspase cascade [41]. Wischhusen et al.
suggested that CP-31398 exerts some effect on the p53 null cell but “an unusual type of apopto-
sis in that caspases appeared to play no role” [24]. In order to distinguish between those
Fig 5. In vitro staining of HCT116 cells treated with 6b (CH I.) and MitoTracker Orange CMTMRos dye
(CH II.).
doi:10.1371/journal.pone.0142678.g005
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pathways, we assayed caspase 3/7 activity. Our results confirmed the observations made by
Wischhusen as CP-31398 did not increase the activity of caspases in p53-/- cells although it was
two times higher than doxorubicin in the wild type cells (Fig 6). On the other hand, styrylqui-
nolines appeared to effectively increase the activity of caspases in a neat correlation to their
cytotoxic activity. Apparently, the activity levels for the most active compounds correspond
with their ability to induce a higher level of caspases in respective cell lines (compare 6b and 3c
in Fig 6).
During the apoptosis, the natural target for caspases is Polys (ADP-rybose) polymerase-1
PARP-1. This protein is responsible for the detection and repair of DNA damage. It is degraded
by caspases during programmed cell death. Cleavage was clearly observable for compounds 6b
and 17b the PARP as shown in Fig 7.
Large aromatic molecules such as styrylquinolines that have a flat structure are believed to
be good DNA intercalators. Based on our results, styrylquinolines may exert their anticancer
activity through mitochondrial mtDNA cleavage, similar to doxorubicin, which has been
proven to intercalate DNA in the nucleus and mitochondria [42,43]. In order to evaluate this
hypothesis, we performed spectrophotometric tests on CT-DNA for the selection of com-
pounds that were tested with referential doxorubicin and CP-31398. The results are shown in
Fig 8 and in more detail in S3 Table. As was expected the strongest hypochromism (decrease of
intensity spectra) can be observed for 5b (41.3%) and 6b (31.0%). Additionally, we also
observed a blue shift of 14 nm in the wavelength, which is characteristic for the DNA-bond of
these compounds. Similar to doxorubicin and CP-31398, we observed a strong decrease in the
Fig 6. Caspase-3/7 activities on the HCT116 cell lines.
doi:10.1371/journal.pone.0142678.g006
Fig 7. Tubulin level (a) and PARP cleavage (b) in HCT-116 cells for 6b (0, 10, 20, 40 μM) and 17b (0, 10,
20, 40, μM).
doi:10.1371/journal.pone.0142678.g007
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Fig 8. Absorption spectra of 2c, 3c, 5b, 6b, CP-31398 and doxorubicin without CT-DNA (solid line) and with CT-DNA (dotted line).
doi:10.1371/journal.pone.0142678.g008
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absorption intensity 34.2% and 41.4%, 37.4%, respectively. Furthermore, the interaction of
doxorubicin with DNA was accompanied by a shift towards higher wavelengths– 10 nm (red
shift).
These results may also elucidate a higher activity of 5b and 6b against HCT116 mutant
cells. Under normal conditions, p53 is responsible for cell cycle arrest and DNA repair when
necessary. A lack of this protein may increase the vulnerability of cells to DNA damage. As was
recently reported, the p53 null cells undergo apoptosis after treatment with DNA damaging
agents while the wild type cells survive after G2 arrest and subsequent DNA repair [44]. With
this in mind, strongly intercalating agents such as 5b and 6b can affect the mutant cells with
stronger effect.
Conclusions
To conclude, a series of twenty-six styrylquinolines was obtained and tested for their antiproli-
ferative activity. Several of the compounds that were tested showed activity at a micromolar
level that was comparable or better than doxorubicin. A positive dependence between lipophili-
city and activity was observed. Despite the structural similarity to the known p53 activator CP-
31398, the styrylquinolines appeared to be active against cancer cells regardless of their p53 sta-
tus. The observation of subcellular accumulations and caspase activation may suggest a mecha-
nism of action that is independent of p53 and based on mitochondrial disintegration. This was
confirmed by intercalation experiments with CT-DNA. Compounds 5b and 6b appeared to be
especially interesting leading structures for developing novel anticancer agents against drug-
resistant lines.
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